SAN MATEO, Calif.–(BUSINESS WIRE)–RapidAI, the leader in advanced imaging for stroke, today announced it has received registration approval and clearance from Argentina’s Administración Nacional de Medicamentos, Alimentos y Tecnología Médica (ANMAT) for the Rapid imaging platform. Rapid is available to hospitals across Argentina, and already in use at Clínica La Sagrada Familia and Fleni.
“Meaningful breakthroughs in stroke care do not come along that often, but Rapid’s clearance in Argentina has had immediate positive effects both for our stroke team and patients,” said Dr. Sebastián Ameriso, Jefe de Centro Integral de Neurología Vascular a Fleni. “Since employing Rapid we have increased mechanical thrombectomy by around 50% compared to the same time last year. Rapid has instantly become a critical weapon in our daily fight against the debilitating and deadly effects of stroke.”
Internationally, Rapid is available in more than 60 countries, and the only clinically validated platform. Rapid is considered by many to be the gold standard for advanced cerebrovascular imaging.
“The AI-powered Rapid platform facilitates faster and more accurate diagnoses in our hospital, where the triage based on the combination between MRI and CT empower the team’s therapeutic decision gaining time during a stroke to save and improve patient lives,” said Dr. Pedro Lylyk, Director del Departamento de Neurociencias Clínica La Sagrada Familia. “During Rapid implementation, in our Institution, Covid-19 struggled Argentina. Collaterally RapidAI improved our workflow to save time during the first wave of the Pandemic. Simply put, that means improved care and better results for all our patients.”
RapidAI makes the most-widely used advanced cerebrovascular imaging products for patient care, research, and clinical trials across the globe. RapidAI clinical products help save lives, RapidAI workflow and messaging technologies help stroke teams save time, and RapidAI analytics and business intelligence products help stroke networks reduce costs and improve patient outcomes.
“Already in use within two of Argentina’s leading stroke centers, we are proud to bring the best in AI-powered stroke imaging to Argentina,” commented Renato Cunha, Vice President of LATAM Sales and Operations at RapidAI. “This is one more important step in making RapidAI’s technology available across LATAM and the World.”
To learn more visit www.RapidAI.com.
About RapidAI
RapidAI is the worldwide leader in advanced cerebrovascular imaging and workflow. Based on intelligence gained over 1 million scans from more than 1,600 hospitals in over 60 countries, the Rapid® platform uses artificial intelligence to create high quality, advanced images from non-contrast CT, CT angiography, CT perfusion, CBCT angiography and MRI diffusion and perfusion scans. The Rapid imaging platform includes Rapid ICH, Rapid ASPECTS, Rapid CTA, Rapid LVO, Rapid CTP, Rapid for Angio and Rapid MRI. RapidAI also offers SurgicalPreview®, a comprehensive aneurysm management platform. RapidAI empowers clinicians to make faster, more accurate diagnostic and treatment decisions for stroke and aneurysm patients using clinically proven, data-driven technology. With its validated, trusted products developed by medical experts, clinicians worldwide are improving patient care and outcomes every day. For more information, visit www.RapidAI.com.
Contacts
Peter Evers
Natron Communications for RapidAI
(415) 524-8899
pr@RapidAI.com
